Balixafortide TFA salt
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H205864

CAS#: 1051366-32-5 (free base)

Description: Balixafortide, also known as POL6326, is an orally bioavailable inhibitor of CXC chemokine receptor 4 (CXCR4) with receptor binding and hematopoietic stem cell-mobilization activities. CXCR4 inhibitor POL6326 binds to the chemokine receptor CXCR4, thereby preventing the binding of stromal derived factor-1 (SDF-1 or CXCL12) to the CXCR4 receptor and subsequent receptor activation. This may induce the mobilization of hematopoietic stem and progenitor cells from the bone marrow into blood. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types.


Chemical Structure

img
Balixafortide TFA salt
CAS# 1051366-32-5 (free base)

Theoretical Analysis

Hodoodo Cat#: H205864
Name: Balixafortide TFA salt
CAS#: 1051366-32-5 (free base)
Chemical Formula: C90H121F9N24O27S2
Exact Mass: 0.00
Molecular Weight: 2,206.205
Elemental Analysis: C, 49.00; H, 5.53; F, 7.75; N, 15.24; O, 19.58; S, 2.91

Price and Availability

Size Price Availability Quantity
5mg USD 345 2 Weeks
10mg USD 585 2 Weeks
25mg USD 1250 2 Weeks
50mg USD 1950 2 Weeks
100mg USD 2950 2 Weeks
Bulk inquiry

Related CAS #: 1051366-32-5 (free base)    

Synonym: POL6326; POL 6326; POL6326; Balixafortide; Ala-cys-ser-ala-pro-arg-tyr-cys-tyr-gln-lys-pro-pro-tyr-his cyclic (2->9)-disulfide TFA salt

IUPAC/Chemical Name: Cyclo(L-alanyl-L-cysteinyl-L-seryl-L-alanyl-D-prolyl-(2S)-2,4-diaminobutanoyl-L-arginyl-L-tyrosyl-L-cysteinyl-L-tyrosyl-L-glutaminyl-L-lysyl-D-prolyl-L-prolyl-L-tyrosyl-L-histidyl), cyclic (2->9)-disulfide with trifluoroacetic acid (1:3)

InChi Key: HALXAXJEIZRORP-QEDQYWNYSA-N

InChi Code: InChI=1S/C84H118N24O21S2.3C2HF3O2/c1-44-70(116)102-62-41-130-131-42-63(77(123)98-57(35-46-14-20-50(110)21-15-46)69(115)68(114)53(10-5-31-91-84(88)89)94-73(119)56(28-30-86)97-79(125)64-11-6-32-106(64)81(127)45(2)93-76(122)61(40-109)101-78(62)124)103-74(120)58(36-47-16-22-51(111)23-17-47)99-72(118)55(26-27-67(87)113)95-71(117)54(9-3-4-29-85)96-80(126)65-12-7-33-107(65)83(129)66-13-8-34-108(66)82(128)60(37-48-18-24-52(112)25-19-48)100-75(121)59(105-104-44)38-49-39-90-43-92-49;3*3-2(4,5)1(6)7/h14-25,39,43-45,53-66,104-105,109-112H,3-13,26-38,40-42,85-86H2,1-2H3,(H2,87,113)(H,90,92)(H,93,122)(H,94,119)(H,95,117)(H,96,126)(H,97,125)(H,98,123)(H,99,118)(H,100,121)(H,101,124)(H,102,116)(H,103,120)(H4,88,89,91);3*(H,6,7)/t44-,45-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63+,64+,65+,66-;;;/m0.../s1

SMILES Code: C[C@@H]1NN[C@H](C(N[C@H](C(N2CCC[C@H]2C(N3CCC[C@@H]3C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H]4CSSC[C@@H](C(N[C@H](C(N[C@H](C(N5CCC[C@@H]5C(N[C@H](C(N[C@H](C(C([C@@H](NC4=O)CC6=CC=C(C=C6)O)=O)=O)CCCNC(N)=N)=O)CCN)=O)=O)C)=O)CO)=O)NC1=O)=O)CC7=CC=C(O)C=C7)=O)CCC(N)=O)=O)CCCCN)=O)=O)=O)CC8=CC=C(O)C=C8)=O)CC9=CN=CN9.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years)

Solubility: Soluble in DMSO, soluble in water.

Shelf Life: >5 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:  POL6326 has successfully completed Phase I clinical trials and is currently being investigated as a stand-alone therapy in a Phase II clinical trial for its efficacy in autologous transplantation of hematopoietic stem cells in multiple myeloma patients. Interim results of the Phase II trial reveal that POL6326 is safe and well tolerated by all enrolled patients. The interim results also show efficacy, in particular a rapid and predictable onset and a dose-dependent mobilization of stem cells. The mobilization, collection of stem cells from the circulating blood (apheresis), analysis and processing of stem cells is completed in one day which represents an important competitive advantage in the hospital compared to standard therapy. (source: http://www.polyphor.com/pol6326.html).        

Biological target:
In vitro activity:
In vivo activity:

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 100.0 45.33
Water 100.0 45.33

Preparing Stock Solutions

The following data is based on the product molecular weight 2,206.20 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

 1: Miao M, De Clercq E, Li G. Clinical significance of chemokine receptor antagonists. Expert Opin Drug Metab Toxicol. 2020 Jan;16(1):11-30. doi: 10.1080/17425255.2020.1711884. Epub 2020 Jan 17. PMID: 31903790.


2: Pernas S, Martin M, Kaufman PA, Gil-Martin M, Gomez Pardo P, Lopez-Tarruella S, Manso L, Ciruelos E, Perez-Fidalgo JA, Hernando C, Ademuyiwa FO, Weilbaecher K, Mayer I, Pluard TJ, Martinez Garcia M, Vahdat L, Perez-Garcia J, Wach A, Barker D, Fung S, Romagnoli B, Cortes J. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. Lancet Oncol. 2018 Jun;19(6):812-824. doi: 10.1016/S1470-2045(18)30147-5. Epub 2018 Apr 26. PMID: 29706375.


3: Robinson T, Escara-Wilke J, Dai J, Zimmermann J, Keller ET. A CXCR4 inhibitor (balixafortide) enhances docetaxel-mediated antitumor activity in a murine model of prostate cancer bone metastasis. Prostate. 2023 May 27. doi: 10.1002/pros.24584. Epub ahead of print. PMID: 37244751.


4: Batur G, Ermert P, Zimmermann J, Obrecht D. Macrocycle Therapeutics to Treat Life-threatening Diseases. Chimia (Aarau). 2021 Jun 30;75(6):508-513. doi: 10.2533/chimia.2021.508. PMID: 34233814.


5: Karpova D, Bräuninger S, Wiercinska E, Krämer A, Stock B, Graff J, Martin H, Wach A, Escot C, Douglas G, Romagnoli B, Chevalier E, Dembowski K, Hooftman L, Bonig H. Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers-results of a dose escalation trial. J Transl Med. 2017 Jan 3;15(1):2. doi: 10.1186/s12967-016-1107-2. PMID: 28049490; PMCID: PMC5209880.


6: Martin M, Mayer IA, Walenkamp AME, Lapa C, Andreeff M, Bobirca A. At the Bedside: Profiling and treating patients with CXCR4-expressing cancers. J Leukoc Biol. 2021 May;109(5):953-967. doi: 10.1002/JLB.5BT1219-714R. Epub 2020 Oct 22. PMID: 33089889.


7: Cortés J, Holgado E, Perez-Garcia J. CXCR4 antagonists for treatment of breast cancer. Oncotarget. 2018 Sep 11;9(71):33442-33443. doi: 10.18632/oncotarget.26090. PMID: 30323888; PMCID: PMC6173365.


8: Huynh C, Dingemanse J, Meyer Zu Schwabedissen HE, Sidharta PN. Relevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditions. Pharmacol Res. 2020 Nov;161:105092. doi: 10.1016/j.phrs.2020.105092. Epub 2020 Aug 3. PMID: 32758634.


9: Derlin T, Hueper K. CXCR4-targeted therapy in breast cancer. Lancet Oncol. 2018 Aug;19(8):e370. doi: 10.1016/S1470-2045(18)30480-7. PMID: 30102220.